Heroin anticraving medications: A systematic review

American Journal of Drug and Alcohol Abuse

Volumn 36, Issue 6, 2010, Pages 332-341

  Fareed, Ayman ^a   Vayalapalli, Sreedevi ^a   Casarella, Jennifer ^a   Amar, Richard ^a   Drexler, Karen ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anticraving; heroin; medications

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; HALOPERIDOL; HYDROMORPHONE; MEMANTINE; METHADONE; NALOXONE; NALTREXONE; PLACEBO; RAPAMYCIN; TETRODOTOXIN;

ARTICLE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERANCE; HEROIN DEPENDENCE; HUMAN; LOW DRUG DOSE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; SYSTEMATIC REVIEW; WITHDRAWAL SYNDROME;

BUPRENORPHINE; HEROIN; HEROIN DEPENDENCE; HUMANS; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 78249250895     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2010.505991     Document Type: Article

References (70)

1. Zijlstra F, Booij J, Brink W, Franken IH. Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol 2008;18:262-270.
2. Sell LA, Morris JS, Bearn J, Frackowiak RSJ, Friston KJ, Dolan RJ. Neural responses associated with cue evoked emotional states and heroin in opiate addicts. Drug Alcohol Depend 2000;60:207-216.
3. Xiao Z, Lee T, Zhang J, Wu Q, Wu R, Weng X, Hu X. Thirsty heroin addicts show different fMRI activations when exposed to water-related and drug-related cues. Drug Alcohol Depend 2006;83:157-162.
4. Shi J, Zhao L, Epstein D, Zhang X, Lu L. Long-term methadone maintenance reduces protracted symptoms of heroin abstinence and cue-induced craving in Chinese heroin abusers. Pharmacol Biochem Behav 2007;87:141-145.
5. Shi J, Zhao L, Copersino M, Fang Y, Chen Y, Tian J, Deng Y, Shuai Y, Jin J, Lu L. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users. Eur J Pharmacol 2008;579:160-166.
6. Sinha R, Catapano D, O'Malley S. Stress-induced craving and stress response in cocaine dependent individuals. Psychopharmacology 1999;142:343-351.
7. Sinha R, Fuse T, Aubin LR, O'Malley S. Psychological, stress drugrelated cues and cocaine craving. Psychopharmacology 2000;152:140-148.
8. Langleben D, Ruparel K, Elman I, Busch-Winokur S, Pratiwadi R, Loughead J, O'Brien C, Childress A. Acute effect of methadone maintenance dose on brain fMRI response to heroin-related cues. Am J Psychiatry 2008 Mar; 165:3.
9. Fareed A, Vayalapalli S, Stout S, Casarella, J, Amar R, Smith-Cox J, Drexler K. Effect of methadone maintenance treatment on heroin craving, a literature review. Journal of addictive diseases (in press).
10. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride. JAMA 1965;193:80-84.
11. Dole VP, Nyswander ME. Rehabilitation of heroin addicts after blockade with methadone. N Y State J Med 1966;66:2011-2017.
12. Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. J Psychiatr Pract 2009 May; 15(3):227-234.
13. Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Methadone maintenance dosing guidelines for opioid dependence, a literature review. J Addict Dis 2010;29(1):1-14.
14. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services and Outcome. New York: Springer-Verlag, 1991.
15. Eissenberg T, Bigelow GE, Strain EC, Walsh SL, Brooner RK, Stitzer ML, Johnson RE. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence: A randomized clinical trial. JAMA 1997;277:1945-1951.
16. Ling W, Charuvastra VC, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts. A Veterans Administration cooperative study. Arch Gen Psychiatry 1976;33:709-720.
17. Fareed A, Roberts M, Sleboda M, Casarella J, Amar R, Drexler K. High dose versus moderate dose methadone maintenance, is there a better outcome. J Addict Dis 2009;28(4):399-405.
18. Farré M, Mas A, Torrens M, Moreno V, Camí J. Retention rate and illicit opioid use during methadone maintenance interventions: A meta-analysis. Drug Alcohol Depend. 2002 Feb. 1; 65(3):283-290.
19. Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, Friedland GH. Heroin use during methadone maintenance treatment: The importance of methadone dose and cocaine use. Am J Public Health 1995 Jan; 85(1):83-88.
20. Shi J, Liu T, Wang X, Epstein D, Zhao L, Zhang X, Lu L, Tetrodotoxin reduces cue-induced drug craving and anxiety in abstinent heroin addicts. Pharmacol Biochem Behav 2009;92:603-607.
21. Shi J, Jun. W, Zhao L, Xue Y, Zhang X, Kosten T, Lu L, Effect of rapamycin on cue-induced drug craving in abstinent heroin addicts. Eur J Pharmacol 2009;615:108-112.
22. White J, Bell J, Saunders J, Williamson P, Makowska M, Farquharson A, Beebe K, Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 2009;103:37-43.
23. Hyman S, Fox H, Hong K, Doebrick C, Sinha R, Brown LS, Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA, Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment. Exp Clin Psychopharmacol 2007;15(2):134-143.
24. Dijkstra B, De Jong C, Bluschke S, Krabbe P, van der Staak CP. Does naltrexone affect craving in abstinent opioid dependent patients? Addict Biol 2007;12:176-182.
25. Comer S, Sullivan M. Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology 2007;193:235-245.
26. Franken I, Hendriks V, Stam C, Brink W. A role for dopamine in the processing of drug cues in heroin dependent patients. Eur Neuropsychopharmacol 2004;14:503-508.
27. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N. Engl. J. Med. 2003;349(10):949-958.
28. Greenwald M, Schuh K, Hopper J, Schuster C, Johanson C. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology 2002;160:344-352.
29. Comer S, Collins E, Fischman MW. Buprenorphine sublingual tablets: Effects on IV heroin self-administration by humans. Psychopharmacology 2001;154:28-37.
30. Greenwald M, Johanson C, Schuster C. Opioid reinforcement in heroindependent volunteers during outpatient buprenorphine maintenance. Drug Alcohol Depend 1999;56:191-203.
31. Ling W, Charuvastra C, Collins J, Batki S, Brown LS, Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA, Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998;93(4):475-486.
32. Cowan A. Buprenorphine: The basic pharmacology revisited. J Addict Med 2007 Jun; 1(2):68-72.
33. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin dependent patients. Ann Intern Med 2000;133(1):40-54.
34. Fiellin DA, O'Connor PG. Office-based treatment of opioid dependent patients. N Engl J Med 2002:347 (11):339-345.
35. Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: Reaching newpatient populations. Am J Psychiatry 2001;158:1200-1204.
36. Marsch LA, Stephens MA, Mudric T, Strain EC, Bigelow GE, Johnson RE. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Exp Clin Psychopharmacol 2005;13:293-302.
37. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and METH for opioid dependence. N Engl J Med 2000;343:1290-1297.
38. Eder H, Fischer G, Gombas W, Jagsch R, Stuhlinger G, Kasper S. Comparison of buprenorphine and METH maintenance in opiate addicts. Eur Addict Res 1998;4(Supplement 1):3-7. (Pubitemid 28478987)
39. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: Self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol 1996;16:58-67.
40. Ling W, Wesson D. Clinical efficacy of buprenorphine: Comparisons to methadone and placebo. Drug Alcohol Depend 2003;70: S49-S57.
41. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993;181:358-364. (Pubitemid 24259606)
42. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996;53:401-407.
43. Mello NK, Bree MP, Mendelson JH. Comparison of buprenorphine and methadone effects on opiate self-administration in primates. J Pharmacol Exp Ther 1983;225:378-386.
44. Mendelson JH, Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994;151:1025-1030.
45. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine versus methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997;54:713-720.
46. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependent cocaine users. Psychopharmacology (Berl) 1994a; 116:401-406.
47. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994b; 151(7):1025-1030.
48. Uehlinger C, Deglon J, Livoti S, Petitjean S, Waldvogel D, Ladewig D. Comparison of buprenorphine and methadone in treatment of opioid dependence. Swiss multicenter study. Eur Addict Res 1998;4(Supplement 1):13-18.
49. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry 1996;53:401-407.
50. Mattick R, Ali R, White J, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients, Addiction 2003;98:441-452.
51. Greenwald M. Heroin craving and drug use in opioid-maintained volunteers: Effects of methadone dose variations. Exp Clin Psychopharmacol 2002;10(1):39-46.
52. Ilgen M, Jain A, Kim H, Trafton J. The effect of stress on craving for methadone depends on the timing of last methadone dose. Behav Res Ther 2008;46:1170-1175.
53. Childress AR, McLellan AT, O'Brien CP. Conditioned responses in a methadone population. A comparison of laboratory, clinic, and natural settings. J Subst Abuse Treat 1986;3:173-179.
54. Walter M, Wiesbeck G, Bloch N, Aeschbach S, Olbrich H, Seifritz E, Dürsteler-MacFarland K. Psychobiological responses to drug cues before and after methadone intake in heroin-dependent patients: A pilot study. Eur Neuropsychopharmacol 2008;18:390-393.
55. Curran H, Bolton J, Wanigaratne S, Smyth C. Additional methadone increases craving for heroin: A double-blind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment. Addiction 1999;94(5):665-674.
56. De Vos J, Ufkes J, Vandenbrink W, Vanbrussel G, Wolff F, Craving patterns in methadone maintenance treatment with dextromoramide as adjuvant. Addict Behav 1999;24(5):707-713.
57. Curran H, Kleckham J, Bearn J, Strang J, Wanigaratne S. Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: A dose-response study. Psychopharmacology 2001;154:153-160.
58. Dawe S, Gray J. Craving and drug reward: A comparison of methadone and clonidine in detoxifying opiate addicts. Drug Alcohol Depend 1995;9:207-212.
59. Fareed A, Vayalapalli S, Byrd Sellers J, Casarella J, Drexler K, Amar J, Cox J, Shaw-Lutchman T. Onsite QTc interval screening for patients in methadone maintenance treatment. J Addict Dis 2010;29(1):15-22.
60. Fareed A, Musselman D, Byrd-Sellers J, Vayalapalli S, Casarella C, Drexler K, Phillips L. On-site basic health screening and brief health counseling of chronic medical conditions for veterans in methadone maintenance treatment. J Addict Med 2010, Vol. 4(3) 160-66.
61. Bekinschtein P, Katche C, Slipczuk LN, Igaz LM, Cammarota M, Izquierdo I, Medina JH. mTOR signaling in the hippocampus is necessary for memory formation. Neurobiol Learn Mem 2007;87:303-307.
62. Parsons RG, Gafford GM, Helmstetter FJ. Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons. J Neurosci 2006;26:12977-12983.
63. Fuchs RA, See RE. Basolateral amygdala inactivation abolishes conditioned stimulus and heroin-induced reinstatement of extinguished heroinseeking behavior in rats. Psychopharmacology (Berl) 2002;160:425-433.
64. Chen S, Ren L, Huang Z. Effects of tetrodotoxin on naloxone-precipitated withdrawal syndrome in morphine-dependent rats and mice. Chin J Pharmcol Toxicol 2001;15:434-440.
65. Popik P, Wrobel M, Bisaga A. Reinstatement of morphine conditioned reward is blocked by memantine. Neuropsychopharmacology 2006;31(1):160-170.
66. Ribeiro Do Couto B, Aguilar MA, Manzanedo C, Rodriguez-Arias M, Minarro J. NMDA glutamate but not dopamine antagonists blocks druginduced reinstatement of morphine place preference. Brain Res Bull 2005;64(6):493-503.
67. Gerra G, Fantoma A, Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 2006 Nov; 20(6):806-814.
68. Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Jr, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA clinical trials network field experience. Am J Addict 2004;13(Supplement 1): S42-S66.
69. Egan JE, Casadonte P, Gartenmann T, Martin J, McCance-Katz EF, Netherland J, Renner JA, Weiss L, Saxon AJ, Fiellin DA, The physician clinical support system-buprenorphine (PCSS-B): A novel project to expand/improve buprenorphine treatment. J Gen Intern Med 2010 May 11. [Epub ahead of print].
70. Gordon A, Liberto J, Granda S, Salmon-Cox S, Andrée T, McNicholas L. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addict 2008;17:459-462.